Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
Summary Background Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus pacl...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2013-02, Vol.14 (2), p.125-133 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 133 |
|---|---|
| container_issue | 2 |
| container_start_page | 125 |
| container_title | The lancet oncology |
| container_volume | 14 |
| creator | Lang, Istvan, Prof Brodowicz, Thomas, MD Ryvo, Larisa, MD Kahan, Zsuzsanna, Prof Greil, Richard, Prof Beslija, Semir, MD Stemmer, Salomon M, MD Kaufman, Bella, MD Zvirbule, Zanete, MD Steger, Günther G, MD Melichar, Bohuslav, Prof Pienkowski, Tadeusz, MD Sirbu, Daniela, MD Messinger, Diethelm, MSc Zielinski, Christoph, Prof |
| description | Summary Background Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. We compared the efficacy of the two regimens. Methods In this open-label, non-inferiority, phase 3 trial, patients with HER2-negative metastatic breast cancer who had received no chemotherapy for advanced disease were randomised (by computer-generated sequence; 1:1 ratio; block size six; stratified by hormone receptor status, country, and menopausal status) to receive either intravenous bevacizumab (10 mg/kg on days 1 and 15) plus intravenous paclitaxel (90 mg/m2 on days 1, 8, and 15) repeated every 4 weeks (paclitaxel group) or intravenous bevacizumab (15 mg/kg on day 1) plus oral capecitabine (1000 mg/m2 twice daily on days 1–14) repeated every 3 weeks (capecitabine group) until disease progression or unacceptable toxic effects. Treatment allocation was not masked because of the differences in routes of administration and cycle lengths. The primary objective was to show non-inferior overall survival with bevacizumab plus capecitabine versus bevacizumab plus paclitaxel. We report results of an interim overall survival analysis, which was planned for after 175 deaths in the per-protocol population. This trial is registered with ClinicalTrials.gov , number NCT00600340. Findings Between Sept 10, 2008, and Aug 30, 2010, we randomised 564 patients (paclitaxel group n=285; capecitabine group n=279) from 51 centres in 12 countries. The per-protocol population consisted of 533 patients (paclitaxel group n=268; capecitabine group n=265). After median follow-up of 18·6 months (IQR 14·9–24·7), 181 patients in the per-protocol population had died (89 [33%] in the paclitaxel group; 92 [35%] in the capecitabine group). The hazard ratio [HR] for overall survival was 1·04 (97·5% repeated CI −∞ to 1·69; p=0·059); the non-inferiority criterion of the interim analysis (interim α=0·00105) was not met. More patients who received bevacizumab plus paclitaxel had an objective response than did those who received bevacizumab plus capecitabine (125 [44%] of 285 patients vs 76 [27%] of 279; p |
| doi_str_mv | 10.1016/S1470-2045(12)70566-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751227791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1470204512705661</els_id><sourcerecordid>1751213305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-47153676a5b67e30dc5a394f6cb58bcf72ee44c80a1e751cdd3a6c80454ef93d3</originalsourceid><addsrcrecordid>eNqNkstu1DAUhiMEohd4BJAlNkWagC9xkukC1JZCkSoqlenacpxj6uLYwXZGDM_Lg-CZKSDNBlb2sb7z-1z-onhG8CuCSf36M6kaXFJc8SNCXzaY13VJHhT7-bkqedW2Dzf3LbJXHMR4hzFpCOaPiz3KGKFt2-4XP09hKZX5MQ2yQ6OdIhqlsibJ72DREkLML90uouQIKjOdcYBkRNqEmEq7jlIAmQZwCWkf0MX5NS0dfJHJLAENkGRM-a5Ql7GYspBTEI6RcQmCGRBobZRUKxQgTjZF5DVKt4CCdL0fTIR-hvwIrrSyAztDzrvSOJ1zfTBpNUPjrYyAGFrcXJ98ene1yPUYaZ8Uj7S0EZ7en4fFzfvzxdlFeXn14ePZyWWpOKlSWTWEs7qpJe_qBhjuFZdsXuladbztlG4oQFWpFksCDSeq75msc1jxCvSc9eywONrqjsF_myAmkWtWYK104KcoSM6itGnm5P9QwhjmGX2xg975KbjciCCMzClmdc0yxbeUCj7GAFqMeaIyrATBYu0YsXGMWNtBECo2jhHrQp7fq0_dAP2frN8WycDbLQB5cksDQURlIO-tNwFUEr03__zizY5CdpjLi7ZfYQXxbzciUoG3ImsNQjcKhP0CH2folA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1319203663</pqid></control><display><type>article</type><title>Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lang, Istvan, Prof ; Brodowicz, Thomas, MD ; Ryvo, Larisa, MD ; Kahan, Zsuzsanna, Prof ; Greil, Richard, Prof ; Beslija, Semir, MD ; Stemmer, Salomon M, MD ; Kaufman, Bella, MD ; Zvirbule, Zanete, MD ; Steger, Günther G, MD ; Melichar, Bohuslav, Prof ; Pienkowski, Tadeusz, MD ; Sirbu, Daniela, MD ; Messinger, Diethelm, MSc ; Zielinski, Christoph, Prof</creator><creatorcontrib>Lang, Istvan, Prof ; Brodowicz, Thomas, MD ; Ryvo, Larisa, MD ; Kahan, Zsuzsanna, Prof ; Greil, Richard, Prof ; Beslija, Semir, MD ; Stemmer, Salomon M, MD ; Kaufman, Bella, MD ; Zvirbule, Zanete, MD ; Steger, Günther G, MD ; Melichar, Bohuslav, Prof ; Pienkowski, Tadeusz, MD ; Sirbu, Daniela, MD ; Messinger, Diethelm, MSc ; Zielinski, Christoph, Prof ; on behalf of the Central European Cooperative Oncology Group ; Central European Cooperative Oncology Group</creatorcontrib><description>Summary Background Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. We compared the efficacy of the two regimens. Methods In this open-label, non-inferiority, phase 3 trial, patients with HER2-negative metastatic breast cancer who had received no chemotherapy for advanced disease were randomised (by computer-generated sequence; 1:1 ratio; block size six; stratified by hormone receptor status, country, and menopausal status) to receive either intravenous bevacizumab (10 mg/kg on days 1 and 15) plus intravenous paclitaxel (90 mg/m2 on days 1, 8, and 15) repeated every 4 weeks (paclitaxel group) or intravenous bevacizumab (15 mg/kg on day 1) plus oral capecitabine (1000 mg/m2 twice daily on days 1–14) repeated every 3 weeks (capecitabine group) until disease progression or unacceptable toxic effects. Treatment allocation was not masked because of the differences in routes of administration and cycle lengths. The primary objective was to show non-inferior overall survival with bevacizumab plus capecitabine versus bevacizumab plus paclitaxel. We report results of an interim overall survival analysis, which was planned for after 175 deaths in the per-protocol population. This trial is registered with ClinicalTrials.gov , number NCT00600340. Findings Between Sept 10, 2008, and Aug 30, 2010, we randomised 564 patients (paclitaxel group n=285; capecitabine group n=279) from 51 centres in 12 countries. The per-protocol population consisted of 533 patients (paclitaxel group n=268; capecitabine group n=265). After median follow-up of 18·6 months (IQR 14·9–24·7), 181 patients in the per-protocol population had died (89 [33%] in the paclitaxel group; 92 [35%] in the capecitabine group). The hazard ratio [HR] for overall survival was 1·04 (97·5% repeated CI −∞ to 1·69; p=0·059); the non-inferiority criterion of the interim analysis (interim α=0·00105) was not met. More patients who received bevacizumab plus paclitaxel had an objective response than did those who received bevacizumab plus capecitabine (125 [44%] of 285 patients vs 76 [27%] of 279; p<0·0001). Similarly, progression-free survival was significantly longer in the paclitaxel group than in the capecitabine group (median progression-free survival 11·0 months [95% CI 10·4–12·9] vs 8·1 months [7·1–9·2]; HR 1·36 [95% CI 1·09–1·68], p=0·0052). The most common adverse events of grade 3 or higher were neutropenia (51 [18%]), peripheral neuropathy (39 [14%]), and leucopenia (20 [7%]) in the paclitaxel group and hand-foot syndrome (44 [16%]), hypertension (16 [6%]), and diarrhoea (15 [5%]) in the capecitabine group. One treatment-related death occurred in the paclitaxel group; no deaths in the capecitabine group were deemed to be treatment-related. Interpretation In this planned interim analysis, the non-inferiority criterion was not met and overall survival results are inconclusive. Final results are expected in 2014. Progression-free survival was better, and more patients achieved an objective response, with bevacizumab plus paclitaxel than with bevacizumab plus capecitabine. Efficacy results in both groups were consistent with previous reports. Funding Central European Cooperative Oncology Group; Roche.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(12)70566-1</identifier><identifier>PMID: 23312888</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject><![CDATA[Aged ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer therapies ; Capecitabine ; Chemotherapy ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Fluorouracil - therapeutic use ; Hematology, Oncology and Palliative Medicine ; Humans ; Hypotheses ; Metastasis ; Middle Aged ; Neoplasm Metastasis ; Paclitaxel - administration & dosage ; Paclitaxel - therapeutic use ; Quality of life ; Receptor, ErbB-2 ; Survival analysis]]></subject><ispartof>The lancet oncology, 2013-02, Vol.14 (2), p.125-133</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Feb 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c514t-47153676a5b67e30dc5a394f6cb58bcf72ee44c80a1e751cdd3a6c80454ef93d3</citedby><cites>FETCH-LOGICAL-c514t-47153676a5b67e30dc5a394f6cb58bcf72ee44c80a1e751cdd3a6c80454ef93d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1470204512705661$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23312888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lang, Istvan, Prof</creatorcontrib><creatorcontrib>Brodowicz, Thomas, MD</creatorcontrib><creatorcontrib>Ryvo, Larisa, MD</creatorcontrib><creatorcontrib>Kahan, Zsuzsanna, Prof</creatorcontrib><creatorcontrib>Greil, Richard, Prof</creatorcontrib><creatorcontrib>Beslija, Semir, MD</creatorcontrib><creatorcontrib>Stemmer, Salomon M, MD</creatorcontrib><creatorcontrib>Kaufman, Bella, MD</creatorcontrib><creatorcontrib>Zvirbule, Zanete, MD</creatorcontrib><creatorcontrib>Steger, Günther G, MD</creatorcontrib><creatorcontrib>Melichar, Bohuslav, Prof</creatorcontrib><creatorcontrib>Pienkowski, Tadeusz, MD</creatorcontrib><creatorcontrib>Sirbu, Daniela, MD</creatorcontrib><creatorcontrib>Messinger, Diethelm, MSc</creatorcontrib><creatorcontrib>Zielinski, Christoph, Prof</creatorcontrib><creatorcontrib>on behalf of the Central European Cooperative Oncology Group</creatorcontrib><creatorcontrib>Central European Cooperative Oncology Group</creatorcontrib><title>Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Summary Background Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. We compared the efficacy of the two regimens. Methods In this open-label, non-inferiority, phase 3 trial, patients with HER2-negative metastatic breast cancer who had received no chemotherapy for advanced disease were randomised (by computer-generated sequence; 1:1 ratio; block size six; stratified by hormone receptor status, country, and menopausal status) to receive either intravenous bevacizumab (10 mg/kg on days 1 and 15) plus intravenous paclitaxel (90 mg/m2 on days 1, 8, and 15) repeated every 4 weeks (paclitaxel group) or intravenous bevacizumab (15 mg/kg on day 1) plus oral capecitabine (1000 mg/m2 twice daily on days 1–14) repeated every 3 weeks (capecitabine group) until disease progression or unacceptable toxic effects. Treatment allocation was not masked because of the differences in routes of administration and cycle lengths. The primary objective was to show non-inferior overall survival with bevacizumab plus capecitabine versus bevacizumab plus paclitaxel. We report results of an interim overall survival analysis, which was planned for after 175 deaths in the per-protocol population. This trial is registered with ClinicalTrials.gov , number NCT00600340. Findings Between Sept 10, 2008, and Aug 30, 2010, we randomised 564 patients (paclitaxel group n=285; capecitabine group n=279) from 51 centres in 12 countries. The per-protocol population consisted of 533 patients (paclitaxel group n=268; capecitabine group n=265). After median follow-up of 18·6 months (IQR 14·9–24·7), 181 patients in the per-protocol population had died (89 [33%] in the paclitaxel group; 92 [35%] in the capecitabine group). The hazard ratio [HR] for overall survival was 1·04 (97·5% repeated CI −∞ to 1·69; p=0·059); the non-inferiority criterion of the interim analysis (interim α=0·00105) was not met. More patients who received bevacizumab plus paclitaxel had an objective response than did those who received bevacizumab plus capecitabine (125 [44%] of 285 patients vs 76 [27%] of 279; p<0·0001). Similarly, progression-free survival was significantly longer in the paclitaxel group than in the capecitabine group (median progression-free survival 11·0 months [95% CI 10·4–12·9] vs 8·1 months [7·1–9·2]; HR 1·36 [95% CI 1·09–1·68], p=0·0052). The most common adverse events of grade 3 or higher were neutropenia (51 [18%]), peripheral neuropathy (39 [14%]), and leucopenia (20 [7%]) in the paclitaxel group and hand-foot syndrome (44 [16%]), hypertension (16 [6%]), and diarrhoea (15 [5%]) in the capecitabine group. One treatment-related death occurred in the paclitaxel group; no deaths in the capecitabine group were deemed to be treatment-related. Interpretation In this planned interim analysis, the non-inferiority criterion was not met and overall survival results are inconclusive. Final results are expected in 2014. Progression-free survival was better, and more patients achieved an objective response, with bevacizumab plus paclitaxel than with bevacizumab plus capecitabine. Efficacy results in both groups were consistent with previous reports. Funding Central European Cooperative Oncology Group; Roche.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Capecitabine</subject><subject>Chemotherapy</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Fluorouracil - therapeutic use</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - therapeutic use</subject><subject>Quality of life</subject><subject>Receptor, ErbB-2</subject><subject>Survival analysis</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkstu1DAUhiMEohd4BJAlNkWagC9xkukC1JZCkSoqlenacpxj6uLYwXZGDM_Lg-CZKSDNBlb2sb7z-1z-onhG8CuCSf36M6kaXFJc8SNCXzaY13VJHhT7-bkqedW2Dzf3LbJXHMR4hzFpCOaPiz3KGKFt2-4XP09hKZX5MQ2yQ6OdIhqlsibJ72DREkLML90uouQIKjOdcYBkRNqEmEq7jlIAmQZwCWkf0MX5NS0dfJHJLAENkGRM-a5Ql7GYspBTEI6RcQmCGRBobZRUKxQgTjZF5DVKt4CCdL0fTIR-hvwIrrSyAztDzrvSOJ1zfTBpNUPjrYyAGFrcXJ98ene1yPUYaZ8Uj7S0EZ7en4fFzfvzxdlFeXn14ePZyWWpOKlSWTWEs7qpJe_qBhjuFZdsXuladbztlG4oQFWpFksCDSeq75msc1jxCvSc9eywONrqjsF_myAmkWtWYK104KcoSM6itGnm5P9QwhjmGX2xg975KbjciCCMzClmdc0yxbeUCj7GAFqMeaIyrATBYu0YsXGMWNtBECo2jhHrQp7fq0_dAP2frN8WycDbLQB5cksDQURlIO-tNwFUEr03__zizY5CdpjLi7ZfYQXxbzciUoG3ImsNQjcKhP0CH2folA</recordid><startdate>20130201</startdate><enddate>20130201</enddate><creator>Lang, Istvan, Prof</creator><creator>Brodowicz, Thomas, MD</creator><creator>Ryvo, Larisa, MD</creator><creator>Kahan, Zsuzsanna, Prof</creator><creator>Greil, Richard, Prof</creator><creator>Beslija, Semir, MD</creator><creator>Stemmer, Salomon M, MD</creator><creator>Kaufman, Bella, MD</creator><creator>Zvirbule, Zanete, MD</creator><creator>Steger, Günther G, MD</creator><creator>Melichar, Bohuslav, Prof</creator><creator>Pienkowski, Tadeusz, MD</creator><creator>Sirbu, Daniela, MD</creator><creator>Messinger, Diethelm, MSc</creator><creator>Zielinski, Christoph, Prof</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20130201</creationdate><title>Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial</title><author>Lang, Istvan, Prof ; Brodowicz, Thomas, MD ; Ryvo, Larisa, MD ; Kahan, Zsuzsanna, Prof ; Greil, Richard, Prof ; Beslija, Semir, MD ; Stemmer, Salomon M, MD ; Kaufman, Bella, MD ; Zvirbule, Zanete, MD ; Steger, Günther G, MD ; Melichar, Bohuslav, Prof ; Pienkowski, Tadeusz, MD ; Sirbu, Daniela, MD ; Messinger, Diethelm, MSc ; Zielinski, Christoph, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-47153676a5b67e30dc5a394f6cb58bcf72ee44c80a1e751cdd3a6c80454ef93d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Capecitabine</topic><topic>Chemotherapy</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Fluorouracil - therapeutic use</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - therapeutic use</topic><topic>Quality of life</topic><topic>Receptor, ErbB-2</topic><topic>Survival analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lang, Istvan, Prof</creatorcontrib><creatorcontrib>Brodowicz, Thomas, MD</creatorcontrib><creatorcontrib>Ryvo, Larisa, MD</creatorcontrib><creatorcontrib>Kahan, Zsuzsanna, Prof</creatorcontrib><creatorcontrib>Greil, Richard, Prof</creatorcontrib><creatorcontrib>Beslija, Semir, MD</creatorcontrib><creatorcontrib>Stemmer, Salomon M, MD</creatorcontrib><creatorcontrib>Kaufman, Bella, MD</creatorcontrib><creatorcontrib>Zvirbule, Zanete, MD</creatorcontrib><creatorcontrib>Steger, Günther G, MD</creatorcontrib><creatorcontrib>Melichar, Bohuslav, Prof</creatorcontrib><creatorcontrib>Pienkowski, Tadeusz, MD</creatorcontrib><creatorcontrib>Sirbu, Daniela, MD</creatorcontrib><creatorcontrib>Messinger, Diethelm, MSc</creatorcontrib><creatorcontrib>Zielinski, Christoph, Prof</creatorcontrib><creatorcontrib>on behalf of the Central European Cooperative Oncology Group</creatorcontrib><creatorcontrib>Central European Cooperative Oncology Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lang, Istvan, Prof</au><au>Brodowicz, Thomas, MD</au><au>Ryvo, Larisa, MD</au><au>Kahan, Zsuzsanna, Prof</au><au>Greil, Richard, Prof</au><au>Beslija, Semir, MD</au><au>Stemmer, Salomon M, MD</au><au>Kaufman, Bella, MD</au><au>Zvirbule, Zanete, MD</au><au>Steger, Günther G, MD</au><au>Melichar, Bohuslav, Prof</au><au>Pienkowski, Tadeusz, MD</au><au>Sirbu, Daniela, MD</au><au>Messinger, Diethelm, MSc</au><au>Zielinski, Christoph, Prof</au><aucorp>on behalf of the Central European Cooperative Oncology Group</aucorp><aucorp>Central European Cooperative Oncology Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2013-02-01</date><risdate>2013</risdate><volume>14</volume><issue>2</issue><spage>125</spage><epage>133</epage><pages>125-133</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>Summary Background Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated. We compared the efficacy of the two regimens. Methods In this open-label, non-inferiority, phase 3 trial, patients with HER2-negative metastatic breast cancer who had received no chemotherapy for advanced disease were randomised (by computer-generated sequence; 1:1 ratio; block size six; stratified by hormone receptor status, country, and menopausal status) to receive either intravenous bevacizumab (10 mg/kg on days 1 and 15) plus intravenous paclitaxel (90 mg/m2 on days 1, 8, and 15) repeated every 4 weeks (paclitaxel group) or intravenous bevacizumab (15 mg/kg on day 1) plus oral capecitabine (1000 mg/m2 twice daily on days 1–14) repeated every 3 weeks (capecitabine group) until disease progression or unacceptable toxic effects. Treatment allocation was not masked because of the differences in routes of administration and cycle lengths. The primary objective was to show non-inferior overall survival with bevacizumab plus capecitabine versus bevacizumab plus paclitaxel. We report results of an interim overall survival analysis, which was planned for after 175 deaths in the per-protocol population. This trial is registered with ClinicalTrials.gov , number NCT00600340. Findings Between Sept 10, 2008, and Aug 30, 2010, we randomised 564 patients (paclitaxel group n=285; capecitabine group n=279) from 51 centres in 12 countries. The per-protocol population consisted of 533 patients (paclitaxel group n=268; capecitabine group n=265). After median follow-up of 18·6 months (IQR 14·9–24·7), 181 patients in the per-protocol population had died (89 [33%] in the paclitaxel group; 92 [35%] in the capecitabine group). The hazard ratio [HR] for overall survival was 1·04 (97·5% repeated CI −∞ to 1·69; p=0·059); the non-inferiority criterion of the interim analysis (interim α=0·00105) was not met. More patients who received bevacizumab plus paclitaxel had an objective response than did those who received bevacizumab plus capecitabine (125 [44%] of 285 patients vs 76 [27%] of 279; p<0·0001). Similarly, progression-free survival was significantly longer in the paclitaxel group than in the capecitabine group (median progression-free survival 11·0 months [95% CI 10·4–12·9] vs 8·1 months [7·1–9·2]; HR 1·36 [95% CI 1·09–1·68], p=0·0052). The most common adverse events of grade 3 or higher were neutropenia (51 [18%]), peripheral neuropathy (39 [14%]), and leucopenia (20 [7%]) in the paclitaxel group and hand-foot syndrome (44 [16%]), hypertension (16 [6%]), and diarrhoea (15 [5%]) in the capecitabine group. One treatment-related death occurred in the paclitaxel group; no deaths in the capecitabine group were deemed to be treatment-related. Interpretation In this planned interim analysis, the non-inferiority criterion was not met and overall survival results are inconclusive. Final results are expected in 2014. Progression-free survival was better, and more patients achieved an objective response, with bevacizumab plus paclitaxel than with bevacizumab plus capecitabine. Efficacy results in both groups were consistent with previous reports. Funding Central European Cooperative Oncology Group; Roche.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>23312888</pmid><doi>10.1016/S1470-2045(12)70566-1</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2013-02, Vol.14 (2), p.125-133 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1751227791 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer therapies Capecitabine Chemotherapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use Hematology, Oncology and Palliative Medicine Humans Hypotheses Metastasis Middle Aged Neoplasm Metastasis Paclitaxel - administration & dosage Paclitaxel - therapeutic use Quality of life Receptor, ErbB-2 Survival analysis |
| title | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A46%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bevacizumab%20plus%20paclitaxel%20versus%20bevacizumab%20plus%20capecitabine%20as%20first-line%20treatment%20for%20HER2-negative%20metastatic%20breast%20cancer:%20interim%20efficacy%20results%20of%20the%20randomised,%20open-label,%20non-inferiority,%20phase%203%20TURANDOT%20trial&rft.jtitle=The%20lancet%20oncology&rft.au=Lang,%20Istvan,%20Prof&rft.aucorp=on%20behalf%20of%20the%20Central%20European%20Cooperative%20Oncology%20Group&rft.date=2013-02-01&rft.volume=14&rft.issue=2&rft.spage=125&rft.epage=133&rft.pages=125-133&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(12)70566-1&rft_dat=%3Cproquest_cross%3E1751213305%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1319203663&rft_id=info:pmid/23312888&rft_els_id=1_s2_0_S1470204512705661&rfr_iscdi=true |